GlaxoSmithKline (GSK) was upgraded to a Hold Rating at Intron Health
In a report released today, from Intron Health upgraded GlaxoSmithKline to a Hold, with a price target of p2,000.00.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
In addition to Intron Health, GlaxoSmithKline also received a Hold from UBS’s Matthew Weston in a report issued yesterday. However, on the same day, Barclays maintained a Sell rating on GlaxoSmithKline (LSE: GSK).
Based on GlaxoSmithKline’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of p7.63 billion and a net profit of p1.74 billion. In comparison, last year the company earned a revenue of p7.52 billion and had a net profit of p1.62 billion
Based on the recent corporate insider activity of 330 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GSK in relation to earlier this year.
Read More on GB:GSK:
Disclaimer & DisclosureReport an Issue
- GSK US President Acquires Notional ADS Under Executive Savings Plan
- Nike downgraded, Oscar Health upgraded: Wall Street’s top analyst calls
- GSK’s Nuvalent Deal Strengthens Oncology Pipeline but Near‑Term EPS Dilution and Fully Valued Shares Justify Hold Rating
- GSK Director Hal Barron Takes Governance Role at Quantinuum
- Midday Fly By: OpenAI files for IPO, GSK to acquire Nuvalent
